Results 181 to 190 of about 70,211 (203)

In vitro development of tamoxifen resistance

Endocrine Related Cancer, 1995
B R Westley, F E B May
openaire   +1 more source

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Lancet, The, 2013
Jon Godwin, Richard G Gray, Xavier Bonfill   +2 more
exaly  

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

Lancet, The, 2005
Michael Fx Gnant, Martina Mittlboeck, Richard F Greil   +2 more
exaly  

CYP2D6 and tamoxifen: DNA matters in breast cancer

Nature Reviews Cancer, 2009
Lisa A Carey, Howard L Mcleod
exaly  

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Lancet, The, 2011
Hein Putter, Christos J Markopoulos, John M S Bartlett   +2 more
exaly  

Tamoxifen-resistant cells sensitive to oestradiol

The Lancet Oncology, 2003
openaire   +1 more source

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Lancet, The, 2016
John F Forbes, Ivana Sestak, Anthony Howell   +2 more
exaly  

Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial

Lancet, The, 2011
Augusto Vaglio, Federico Alberici, Umberto Maggiore   +2 more
exaly  

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Lancet, The, 2009
C Kent Osborne
exaly